Laidlaw Goes Too Far
An investment brokerage firm called Laidlaw is trying to take over Relmada Therapeutics, a company that develops treatments for serious pain, and they’re spreading false information to do so. Relmada is fighting back, and the U.S. District Court of Nevada has issued a ruling in their favor. The federal court has issued a restraining order against Laidlaw in general and its principals, Matthew Eitner and James Ahern, in particular; it seems that Laidlaw has finally gone too far.
Laidlaw served as an investment banker to Relmada in the past and apparently liked what they saw. Relmada has been close recently to putting a new product on the market called BuTab, and the market forecast for this pain medication is extremely good. Laidlaw went after the company in an effort to make it their own, but so far they have succeeded only in temporarily distracting Relmada from their work.
About Laidlaw and Company
Laidlaw & Company is an investment bank headquartered in New York City. While they look good on paper, the firm has a reputation for violating finance laws and regulations.
In My Opinion
Personally, I do not like what Laidlaw, led by Matthew Eitner and James Ahern, are up to. When they signed on to help Relmada, they should not have been using the information they gained through working with their client to attempt to acquire it. It seems to me that their actions are certainly unethical and possibly illegal. Hopefully, Relmada will continue to be able to fight them off in the courts and will be able to bring their important pain medications to market unobstructed.